Working… Menu

Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias (AVATAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01780311
Recruitment Status : Unknown
Verified January 2013 by Leonardo Bolognese, MD, Ospedale San Donato.
Recruitment status was:  Recruiting
First Posted : January 31, 2013
Last Update Posted : January 31, 2013
Information provided by (Responsible Party):
Leonardo Bolognese, MD, Ospedale San Donato

Brief Summary:
A randomized, parallel, open study comparing catheter ablation versus antiarrhythmic drugs for outflow tract ventricular arrhythmias

Condition or disease Intervention/treatment Phase
Ventricular Tachycardia Ventricular Premature Complexes Drug: antiarrhythmic drugs (Flecainide or Propafenone or Sotalol) Procedure: Catheter Ablation Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Study Start Date : January 2013
Estimated Primary Completion Date : January 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Antiarrhythmic drugs
Flecainide or Propafenone or Sotalol (oral, standard dosage)
Drug: antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)
Experimental: ABLATION
Catheter Ablation
Procedure: Catheter Ablation

Primary Outcome Measures :
  1. SF-36 score [ Time Frame: 6 months ]
    Quality of life improvement according to SF-36 score variations

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. presence of ventricular ectopic beats (VEB) with left-bundle-branch block morphology or right-bundle-branch block morphology and positive concordance throughout the chest leads, inferior axis and at least one of the following:

  1. >2000 isolated VEB/24h
  2. symptomatic monomorphic ventricular tachycardia
  3. left ventricular disfunction supposed to be due to tachycardia-induced cardiomyopathy

Exclusion Criteria:

  1. known structural heart disease
  2. pregnancy
  3. life expectancy < 1 year

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01780311

Layout table for location information
Cardiovascular Department, Ospedale S.Donato Recruiting
Arezzo, AR, Italy, 52100
Contact: Pasquale Notarstefano, MD   
Principal Investigator: Leonardo Bolognese, MD, FESC         
Principal Investigator: Pasquale Notarstefano, MD         
Sub-Investigator: Simone Grotti         
Sponsors and Collaborators
Ospedale San Donato

Layout table for additonal information
Responsible Party: Leonardo Bolognese, MD, Director, Ospedale San Donato Identifier: NCT01780311     History of Changes
Other Study ID Numbers: Arezzo008
First Posted: January 31, 2013    Key Record Dates
Last Update Posted: January 31, 2013
Last Verified: January 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Tachycardia, Ventricular
Ventricular Premature Complexes
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Pathologic Processes
Cardiac Complexes, Premature
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents